{"doi":"10.1586/eem.11.30","title":"The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist","abstract":null,"journal":"Expert Review of Endocrinology & Metabolism","year":2011,"id":621272,"datarank":0.31191623125197543,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":682627,"name":"Filip K Knop","orcid":null,"position":1,"is_corresponding":false},{"id":197424,"name":"Tina Vilsbøll","orcid":null,"position":2,"is_corresponding":false},{"id":615750,"name":"Mikkel Christensen","orcid":"0000-0003-4291-0611","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist","abstract":"Lixisenatide is a human glucagon-like peptide-1 receptor agonist for the once-daily treatment of Type 2 diabetes mellitus (T2DM). Lixisenatide is based on the structure of exendin-4 (1-39) with C-terminal modification. Clinical trials involving patients with T2DM have provided evidence for improved glucose tolerance, weight loss and lowered hemoglobin A1c (HbA1c) causing a significantly higher percentage of patients to achieve target HbA1c compared with placebo. This article reviews the clinical pharmacology of lixisenatide as well as the GetGoal clinical trial program that aims to make lixisenatide available for the treatment of patients with T2DM.","is_dataset_classified":null,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19767382","pmcid":null,"openalex_id":"https://openalex.org/W2071395483","authors":[],"funders":[],"total_grants":0,"fwci":0.9381,"citation_percentile":0.74601462,"influential_citations":0,"citation_trend":[{"year":2013,"count":4},{"year":2018,"count":1},{"year":2020,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.tandfonline.com/doi/pdf/10.1586/eem.11.30","host_type":"publisher"},{"url":"https://doi.org/10.1586/eem.11.30","host_type":"journal"}],"fields_of_study":["Diabetes Treatment and Management","Metabolism, Diabetes, and Cancer","Pharmacology and Obesity Treatment"],"mesh_terms":[],"keywords":["Lixisenatide","Medicine","Glucagon-like peptide 1 receptor","Agonist","Placebo","Type 2 Diabetes Mellitus","Type 2 diabetes","Internal medicine","Clinical trial","Diabetes mellitus","Pharmacology","Endocrinology","Receptor","Exenatide","Alternative medicine","Pathology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T13:54:53.932235Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}